Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
03/2003
03/06/2003WO2002081709A3 Modified hpv e6 and e7 genes and proteins useful for vaccination
03/06/2003WO2002070470A3 Benzophenones as inhibitors of reverse transcriptase
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002064731A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
03/06/2003WO2002062959A3 Hepatitis b virus treatment
03/06/2003WO2002058692A9 Halogenated composition, method for preparing same and uses thereof
03/06/2003WO2002057224A3 Synthesis and antimicrobial activityof novel dicationic 'reversed amidines'
03/06/2003WO2002056867A3 Extended release pharmaceutical compositions containing beta-lactam antibiotics
03/06/2003WO2002055507A8 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
03/06/2003WO2002050093A3 Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
03/06/2003WO2002045742A8 Lipoteichoic acid immunogenic compositions and methods of making and using thereof
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002022080A9 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
03/06/2003WO2002004018A8 Mid-life vaccine and methods for boosting anti-mycobacterial immunity
03/06/2003WO2002000650A9 Novel compounds possessing antibacterial, antifungal or antitumor activity
03/06/2003WO2001096540A3 Hepatitis c protease exosite for inhibitor design
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001068103A9 Treatment of herpes infection using immunomodulatory polynucleotide sequences
03/06/2003WO2001063539A3 Anti-infective agents useful against multidrug-resistant strains of bacteria
03/06/2003US20030045746 Phosphorous organic compounds and their use
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045726 Novel immunotherapeutic agents
03/06/2003US20030045724 Benzimidazole compound crystal
03/06/2003US20030045715 Useful in treating and suppressing human Cytomegalovirus
03/06/2003US20030045695 Ribozyme for detecting gene sequence
03/06/2003US20030045678 Crystalline or crystal-like lipopeptide for use as bactericides
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045557 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045546 Anticancer agents
03/06/2003US20030045545 Immunomodulators, induce cytokine biosynthesis, and antineoplastic agents
03/06/2003US20030045544 Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045538 Viologen linked acridine based molecule and process for the preparation thereof
03/06/2003US20030045534 Pharmaceutical combination of antiviral agents
03/06/2003US20030045528 Antibacterial and antiprotozoal agents
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045508 Phosphoramidates
03/06/2003US20030045501 Use of atazanavir in HIV therapy
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045484 Crystallizing amorphous daptomycin from a crystallization solution comprising a cation from a salt, a buffer, an organic precipitant, and a low molecular weight alcohol.
03/06/2003US20030045483 Novel substance having physiological activity, process for producing the same, and use
03/06/2003US20030045481 Use of specific amino acids reduces or prevents coloration attributable to a saccharide stabilizer; especially useful in pharmacologically active proteinaceous compositions
03/06/2003US20030045479 Novel N-formyl hydroxylamine compounds, compositions and methods of use
03/06/2003US20030045478 Treating diseases such as cardiac and cerebral ischemia or reperfusion injury, sepsis and bacterial meningitis.
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030045460 Orally administered peptides to ameliorate atherosclerosis
03/06/2003US20030045457 Process for preparing glycopeptide derivatives
03/06/2003US20030045450 Administering a glycine-site antagonist at the NMDA receptor, e.g., felbamate, for spasticity, symptomatic depression or to protect cells from the consequences of obesity
03/06/2003US20030044960 Picornaviruses, vaccines and diagnostic kits
03/06/2003US20030044915 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044888 Polypeptide for use in the treatment of addison's disease
03/06/2003US20030044863 Diagnosing cancer in humans; obtain tissue sample, detect invasive complexes associated tissus, evaluate for cancer
03/06/2003US20030044824 Preincubation assay methods
03/06/2003US20030044773 Genetically engineering viral polypeptide; obtain nucleotide sequences coding polypeptide, insert codon, clone into vector, transform cell, detect expression of genetically engineered polypeptide
03/06/2003US20030044452 Composition for topical administration
03/06/2003US20030044450 Oral vaccines
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044428 Significantly improves ability of many HIV infected individuals to maintain suppression of HIV replication to low levels for an extended period of time; AIDS therapy
03/06/2003US20030044414 Vaccine which neutralizes bacteria or protozoa
03/06/2003US20030044397 In digestable carrier; therapy for liver disorders
03/06/2003DE10129369C1 Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats Water-soluble, an amino sugar exhibiting antibiotic in the form of a pole ysaccharid conjugate
03/06/2003CA2458924A1 Casein derived peptides and uses thereof in therapy
03/06/2003CA2458854A1 Helicobacter pylori vaccination
03/06/2003CA2458561A1 Yeast membrane protein expression system and its application in drug screening
03/06/2003CA2458559A1 Gene of novel corynebacterium diphtheriae antigen
03/06/2003CA2458477A1 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458408A1 Mutagenic nucleoside analogs for the treatment of viral disease
03/06/2003CA2458219A1 Oral rinse for treatment or prevention of bacterial and fungal infection
03/06/2003CA2458135A1 Single dose azithromycin for treating respiratory infections
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2458040A1 Antiviral protease inhibitors
03/06/2003CA2457885A1 Antimicrobial and anti-inflammatory peptides
03/06/2003CA2457779A1 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
03/06/2003CA2457532A1 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003CA2457488A1 Antimicrobial agent
03/06/2003CA2456350A1 Novel imidazopyridine compounds with therapeutic effect
03/06/2003CA2456323A1 Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
03/06/2003CA2455504A1 Anti-bacterial agents based upon oxoanion binding
03/05/2003WO2002020566A2 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3?
03/05/2003EP1288299A2 TRNA synthetase
03/05/2003EP1288298A2 TRNA synthetase from Staphylococcus aureus
03/05/2003EP1288292A1 Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288222A1 Peptidic compounds selectively binding to P-selectin
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
03/05/2003EP1287829A1 An ayurvedic preparation as a sedative, heart tonic compound and as a resistive urinary infection remedy
03/05/2003EP1287156A2 Tnf and ifn stimulated genes and uses therefor
03/05/2003EP1287142A1 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide
03/05/2003EP1287137A2 REGULATION OF HUMAN $g(a)1A?ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287120A2 Human circulating dendritic cell compositions and methods
03/05/2003EP1287024A2 Virulence genes, proteins, and their use
03/05/2003EP1287020A2 Cancer diagnosis and assays for screening anti-cancer agents
03/05/2003EP1287011A1 Hygromycin a derivatives for the treatment of bacterial and protozoal infections
1 ... 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 ... 1798